|View printer-friendly version|
Incorporates new molecular entity for migraine and Axsome’s MoSEIC™ technology
Potential for superior efficacy as compared to current treatments
FDA Pre-IND meeting written guidance received
Issued U.S. patent provides protection into 2036
Phase 3 trial anticipated in 2018
Axsome has received, from the
“Migraine attacks are disabling and affect more than 37 million Americans,” said
The U.S. Patent and Trademark Office recently issued patent number 9,821,075 which covers MoSEIC meloxicam and provides protection for AXS-07 into 2036.
“AXS-07 is the second product candidate stemming from our MoSEIC platform which has the potential to generate additional proprietary new medicines,” added Dr. Tabuteau. “We are excited about the prospects of AXS-07 to address unmet medical needs in this important neurological condition and look forward to advancing it in late stage clinical trials as early as this coming year.”
The rationale for the development of AXS-07 in the treatment of migraine is based on the rapid absorption and long half-life of MoSEIC meloxicam, and the additive and potentially synergistic efficacy resulting from the distinct mechanisms of action of meloxicam and rizatriptan.
The meloxicam component of AXS-07 is a COX-2 preferential non-steroidal anti-inflammatory drug that inhibits the synthesis of prostaglandins, may reduce meningeal inflammation and inhibit central sensitization resulting from the activation of glial cells in the brain stem. Meloxicam is a new molecular entity for migraine and is not currently approved for this indication. Axsome’s MoSEIC technology enables meloxicam’s use in this indication by significantly increasing the speed of its absorption after oral administration, as demonstrated in a completed Phase 1 clinical trial.
The rizatriptan component of AXS-07 is a 5-HT1B/D agonist that inhibits calcitonin gene-related peptide (CGRP)–mediated vasodilation, has been shown to have central trigeminal antinociceptive activity, and may reduce the release of inflammatory mediators from trigeminal nerves. Rizatriptan is currently approved as a single agent for the acute treatment of migraine.
Clinical Profile of AXS-07
Based on AXS-07’s multiple mechanisms of action, the unique pharmacokinetics of the MoSEIC meloxicam component, and results from numerous clinical trials with the rizatriptan component, Axsome believes that AXS-07 may have significant advantages over currently available therapy in the treatment of migraine:
- Rapid absorption and onset of action. In a completed Phase 1 trial, therapeutic plasma levels of meloxicam were attained within 15 minutes of oral dosing of MoSEIC meloxicam, with a median time to maximum plasma concentration (Tmax) that was 9 times faster for MoSEIC meloxicam as compared to standard meloxicam (0.5 hour versus 4.5 hours for MoSEIC and standard meloxicam, respectively, p<0.0001). The fast absorption of MoSEIC meloxicam combined with a reported Tmax for rizatriptan of 1 to 1.5 hours is expected to result in rapid onset of migraine pain relief with AXS-07.
- Strong and consistent pain relief. AXS-07 has the potential to provide efficacy that is superior to currently available migraine treatments based on the expected additive effect of MoSEIC meloxicam and rizatriptan. Clinical experience with rizatriptan as a single agent further indicates that AXS-07 may provide more consistent intra-patient efficacy than currently available migraine treatments, as well as efficacy in various stages, severities, and subtypes of migraine including menstrual migraine.
- Sustained pain relief. The approximately 20-hour half-life of MoSEIC meloxicam, combined with the expected additive effect of the rizatriptan component of AXS-07 is expected to result in more sustained efficacy with less recurrence of symptoms with AXS-07 as compared to currently available treatments.
- Pharmacoeconomic benefits. The potential superior efficacy of AXS-07 would be expected to result in reduced use of medical services, rescue or repeat medication, absenteeism, and loss of productivity, as compared to currently available treatments.
Over 37 million Americans suffer from migraine according to the
AXS-07 is an oral, fixed-dose combination of MoSEIC™ meloxicam and rizatriptan being developed for the acute treatment of migraine. Meloxicam is a new molecular entity for migraine enabled by Axsome’s MoSEIC (
About Axsome’s MoSEIC™ Technology
Axsome’s MoSEIC (
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials, futility analyses and receipt of interim results; the timing of and our ability to obtain and maintain
 Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in
 Smelt AF, Louter MA, Kies DA, Blom JW, Terwindt GM, van der Heijden GJ, De Gucht V, Ferrari MD, Assendelft WJ. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS One. 2014 Jun 16;9(6):e98933.
 Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(suppl 2):S20-S26.